RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
BeiGene, a Beijing oncology company, hopes to raise $1 billion in a debut offering on the Hong Kong stock exchange. The company is already listed on NASDAQ in the US. BeiGene has five drug candidates in clinical trials, and it expects to file NDAs for its two leading candidates in China later this year, including one for a PD-1 molecule. The underwriters are accepting bids this week, and shares will start trading on August 8. BeiGene reported $1.5 billion in cash at its most recent reporting.
Source: China Biotoday
